{"id":2517,"date":"2026-08-10T09:38:07","date_gmt":"2026-08-10T01:38:07","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2517"},"modified":"2026-08-10T09:39:26","modified_gmt":"2026-08-10T01:39:26","slug":"from-macrophage-biology-to-clinical-development-hanchorbio-advances-the-future-of-gastric-cancer-immunotherapy","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/from-macrophage-biology-to-clinical-development-hanchorbio-advances-the-future-of-gastric-cancer-immunotherapy\/","title":{"rendered":"From Macrophage Biology to Clinical Development: HanchorBio Advances the Future of Gastric Cancer Immunotherapy"},"content":{"rendered":"

From Macrophage Biology to Clinical Development:
\nHanchorBio Advances the Future of Gastric Cancer Immunotherapy<\/strong><\/h2>\n

Taiwan Gastric Cancer Experts Forum connects innate immune biology, FBDB\u2122 platform innovation,
\nand the early clinical development of HCB101.<\/em><\/h3>\n

 <\/p>\n

[Taipei, Shanghai, San Francisco | August 10, 2026]<\/strong> \u2014 HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced insights from the \u201cTaiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy\u201d<\/strong>, held August 8\u20139 in Taichung, Taiwan.<\/p>\n

\"\"

Taiwan Gastric Cancer Experts Forum connects innate immune biology, FBDB platform innovation, and the early clinical development of HCB101.<\/p><\/div>\n

The two-day forum brought together leading gastric cancer specialists and translational researchers to address a central question shaping the next era of cancer immunotherapy: \u00a0What comes after PD-1?<\/strong><\/p>\n

 <\/p>\n

While PD-1\/PD-L1 therapies have transformed cancer treatment, many patients continue to experience primary or acquired resistance. Discussions throughout the forum explored how overcoming immune resistance may require a deeper understanding of tumor biology, including innate immune suppression, macrophage function, biomarker-driven patient selection, and next-generation therapeutic engineering.<\/p>\n

 <\/p>\n

The forum showcased HanchorBio\u2019s integrated development strategy:<\/p>\n

Macrophage biology \u2192 FBDB\u2122 platform innovation \u2192 Early clinical development of HCB101<\/strong><\/p>\n

 <\/p>\n

The forum followed HanchorBio\u2019s August 7 announcement of a strategic collaboration with the Taiwan Cancer Moonshot research team led by Professor Sung-Liang Yu of National Taiwan University, reinforcing the Company\u2019s integrated approach:<\/p>\n

Patient Biology \u2192 Translational Insight \u2192 Clinical Evidence \u2192 Development Strategy<\/strong><\/p>\n

 <\/p>\n

\u201cScientific innovation becomes valuable when clinical evidence helps us understand not only whether a therapy works, but where and why the underlying biology works,\u201d said Scott Liu, PhD, Founder and Chairman of HanchorBio<\/strong>. By connecting patient-derived research, translational science, therapeutic engineering, and clinical development, we aim to build a more precise path from discovery to differentiated medicines. Our goal is to understand which patients may benefit, what biology drives response or resistance, and how emerging evidence should guide future clinical strategies.\u201d<\/p>\n

 <\/p>\n

Advancing Innate Immune Checkpoint Biology<\/strong><\/p>\n

Alvin Luk, PhD, MBA, President and CMO (Group) & CEO (USA) of HanchorBio<\/strong>, presented the scientific rationale for \u201cTargeting the SIRP\u03b1\u2013CD47 Axis as a Next-Generation Innate Immune Checkpoint<\/em>.”<\/p>\n

The presentation discussed the critical role of macrophages and myeloid-driven immune suppression in shaping the tumor microenvironment, as well as lessons learned from first-generation CD47-directed approaches.<\/p>\n

 <\/p>\n

The discussion further explored how engineered SIRP\u03b1-based therapeutics may address key challenges in innate immune checkpoint modulation, including biological precision, therapeutic window, receptor occupancy, dosing strategy, and combination potential.<\/p>\n

 <\/p>\n

The central message: overcoming immune resistance may require more than activating T cells alone\u2014it requires engaging the innate immune system and harnessing macrophage biology as a critical component of next-generation cancer immunotherapy<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Engineering Next-Generation Immunotherapy<\/strong><\/p>\n

Dr. Liu<\/strong> presented \u201c<\/strong>Emerging Innovation in Next-Generation Immunotherapy for Gastric Cancer<\/em>,\u201d<\/strong> introducing HanchorBio\u2019s FBDB\u2122 platform and its approach to engineering multifunctional biologics designed to integrate complementary immune mechanisms.<\/p>\n

 <\/p>\n

The presentation discussed how structural biology, AI-assisted protein engineering, and translational research can guide the development of differentiated therapeutic architectures with combination potential.<\/p>\n

The goal is not more targets. It is the right biology, translated into the right therapeutic architecture.<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Translating Biology into Clinical Development<\/strong><\/p>\n

Dr. Luk<\/strong> also presented \u201c<\/strong>Early Clinical Development of HCB101<\/em>,\u201d outlining the program\u2019s clinical rationale, pharmacology, emerging clinical experience, and future development strategy in gastric and gastroesophageal junction cancer.<\/p>\n

 <\/p>\n

The presentation covered key translational elements supporting HCB101 development, including safety and tolerability, pharmacokinetics and pharmacodynamics, receptor occupancy, early antitumor activity, durability signals, and future combination strategies.<\/p>\n

 <\/p>\n

\u201cEarly clinical development is not only about determining whether a molecule shows activity,\u201d said Dr. Luk<\/strong>. \u201cThe most valuable data help us understand where the biology works, which treatment settings are most appropriate, and how emerging evidence should guide the next development decision.\u201d<\/p>\n

 <\/p>\n

The forum reinforced a shared vision:<\/p>\n

The future of immuno-oncology will require a deeper understanding of tumor biology, smarter therapeutic engineering, and disciplined clinical translation.<\/strong><\/p>\n

 <\/p>\n

Advancing HCB101 in Gastric Cancer<\/strong><\/p>\n

HCB101 is HanchorBio\u2019s clinical-stage SIRP\u03b1\u2013CD47 program and a lead clinical value driver within the Company\u2019s oncology portfolio.<\/p>\n

 <\/p>\n

By targeting innate immune checkpoint biology and engaging macrophage function, HCB101 represents HanchorBio\u2019s effort to translate differentiated immune biology into clinical development.<\/p>\n

 <\/p>\n

HanchorBio is evaluating HCB101 across multiple tumor types and treatment combinations, including second-line gastric and gastroesophageal junction cancer.<\/p>\n

\u00a0<\/strong><\/p>\n

About HanchorBio<\/strong><\/p>\n

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The Company\u2019s proprietary Fc-based designer biologics (FBDB\u2122) platform enables the engineering of multifunctional biologics with diverse targeting modalities designed to activate innate and adaptive immune pathways and address limitations of current immunotherapies.<\/p>\n

 <\/p>\n

HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations, translational development strategies, and scalable CMC capabilities. For more information, please visit: https:\/\/www.HanchorBio.com<\/a><\/p>\n

\u00a0<\/strong><\/p>\n

Forward-Looking Statements<\/strong><\/p>\n

This press release contains forward-looking statements regarding HanchorBio\u2019s research collaborations, development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions, regulatory decisions, protocol development, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

HanchorBio announced insights from the \u201cTaiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy\u201d, held August 8\u20139 in Taichung, Taiwan.<\/p>\n","protected":false},"featured_media":2516,"template":"","news-category":[36],"class_list":["post-2517","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-events"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2516"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2517"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}